CHMP recommends approving Keytruda® (pembrolizumab) plus Lenvima®/Kisplyz® (lenvatinib) for renal cell cancer and endometrial carcinoma

Oct 15, 2021

Merck and Eisai announced that the CHMP has adopted positive opinions recommending the approval of the combination of Keytruda® (pembrolizumab) plus Lenvima®/Kisplyz® (lenvatinib) for the first-line treatment of adults with advanced renal cell cancer and for the treatment of adults with advanced or recurrent endometrial carcinoma.

Print Page Mail Article